Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3833376

CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.CC#N.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
TSHR P16473 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
DPP4 P27487 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
THRB P10828 1/20 0.32
CA2 P00918 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL140346 1.00 ALDH1A1 (0.35) ALDH1A1TSHRL3MBTL1DPP4DPP8
Trifluoroacetic Acid SCHEMBL27934780 1.00 ALDH1A1 (0.35) ALDH1A1TSHRL3MBTL1DPP4DPP8
Trifluoroacetic Acid SCHEMBL8009450 1.00 ALDH1A1 (0.35) ALDH1A1TSHRL3MBTL1DPP4DPP8
Trifluoroacetic Acid SCHEMBL4287600 1.00 ALDH1A1 (0.35) ALDH1A1TSHRL3MBTL1DPP4DPP8
Trifluoroacetic Acid SCHEMBL4355857 1.00 ALDH1A1 (0.35) ALDH1A1TSHRL3MBTL1DPP4DPP8
Trifluoroacetic Acid SCHEMBL1727596 1.00 ALDH1A1 (0.35) ALDH1A1TSHRL3MBTL1DPP4DPP8
Trifluoroacetic Acid SCHEMBL5745817 1.00 ALDH1A1 (0.35) ALDH1A1TSHRL3MBTL1DPP4DPP8
Trifluoroacetic Acid SCHEMBL128012 1.00 ALDH1A1 (0.35) ALDH1A1TSHRL3MBTL1DPP4DPP8
Trifluoroacetic Acid SCHEMBL18095558 0.97 ALDH1A1 (0.33) ALDH1A1TSHRL3MBTL1DPP4DPP8
Trifluoroacetic Acid SCHEMBL4296530 0.97 ALDH1A1 (0.33) ALDH1A1TSHRL3MBTL1DPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119362-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA H. LUNDBECK A/S (DK) 2022-04-21 US disclosed
US-11059798-B2 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia H. LUNDBECK A/S (DK) 2021-07-13 US disclosed
US-20200131143-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA H. LUNDBECK A/S (DK) 2020-04-30 US disclosed
US-20190031631-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA H. LUNDBECK A/S (DK) 2019-01-31 US disclosed
US-10118907-B2 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia H. LUNDBECK A/S (DK) 2018-11-06 US disclosed
US-20170158650-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA H. LUNDBECK A/S (DK) 2017-06-08 US disclosed
US-9617231-B2 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia H. LUNDBECK A/S (DK) 2017-04-11 US disclosed
US-20160068497-A1 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia H. LUNDBECK A/S (DK) 2016-03-10 US disclosed
US-9216961-B2 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia H. LUNDBECK A/S (DK) 2015-12-22 US disclosed
US-20150307458-A1 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia H. LUNDBECK A/S (DK) 2015-10-29 US disclosed
US-8575174-B2 Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia H. LUNDBECK A/S (DK) 2013-11-05 US disclosed
US-20130281436-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA H. LUNDBECK A/S (DK) 2013-10-24 US disclosed
US-20120322811-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL-INDANES FOR TREATMENT OF SCHIZOPHRENIA H. LUNDBECK A/S (DK) 2012-12-20 US disclosed
EP-1650567-B1 METHOD OF DETECTING PROTEIN DIRT ON CONTACT LENS MENICON CO LTD (JP) 2009-10-07 EP disclosed
EP-1650567-A1 METHOD OF DETECTING PROTEIN DIRT ON CONTACT LENS MENICON CO., LTD. (JP) 2006-04-26 EP disclosed
US-6395737-B1 ANTICOAGULANTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-05-28 US disclosed
CN-1332734-A Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity AVENTIS PHARMA GMBH (DE) 2002-01-23 CN disclosed
EP-1140878-A1 NOVEL MALONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ( INHIBITIO OF FACTOR XA ACTIVITY ) Aventis Pharma Deutschland GmbH (DE) 2001-10-10 EP disclosed
WO-2000040571-A1 NOVEL MALONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM (INHIBITION OF FACTOR XA ACTIVITY) AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-07-13 WO disclosed
EP-1016663-A1 Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) Aventis Pharma Deutschland GmbH (DE) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11059798-B2 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia HTR2C, DRD2, HTR2A ALDH1A1 740/4885TSHR 149/4885L3MBTL1 4292/4885
US-20120322811-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL-INDANES FOR TREATMENT OF SCHIZOPHRENIA HTR2C, DRD2, HTR2A ALDH1A1 729/4885TSHR 172/4885L3MBTL1 4250/4885
US-20200131143-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA HTR2C, DRD2, HTR2A ALDH1A1 740/4885TSHR 149/4885L3MBTL1 4292/4885
US-20130281436-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA HTR2C, DRD2, HTR2A ALDH1A1 740/4885TSHR 149/4885L3MBTL1 4292/4885
US-20220119362-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA HTR2C, DRD2, HTR2A ALDH1A1 740/4885TSHR 149/4885L3MBTL1 4292/4885
US-20160068497-A1 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia HTR2C, DRD2, HTR2A ALDH1A1 740/4885TSHR 149/4885L3MBTL1 4292/4885
US-20170158650-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA HTR2C, DRD2, HTR2A ALDH1A1 740/4885TSHR 149/4885L3MBTL1 4292/4885
US-20190031631-A1 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA HTR2C, DRD2, HTR2A ALDH1A1 740/4885TSHR 149/4885L3MBTL1 4292/4885
US-10118907-B2 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia HTR2C, DRD2, HTR2A ALDH1A1 740/4885TSHR 149/4885L3MBTL1 4292/4885
US-20150307458-A1 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia HTR2C, DRD2, HTR2A ALDH1A1 740/4885TSHR 149/4885L3MBTL1 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.